Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708

Overview

Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1α1 and COL1α2), altering the quantity or quality of type I collagen. Although OI is typically characterized as a disease of the bone, it is perhaps more accurately described as a connective tissue disorder. Type I collagen is a major constituent of lung connective tissue. Respiratory insufficiency is the leading cause of death in patients with OI. Thus, it is important and necessary to understand the etiology of the restrictive pulmonary physiology in the OI population.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: December 1, 2024

Detailed Description

This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. Evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. Eighteen participants will be enrolled, ideally within one year. Participants will be enrolled regardless of OI type since Bronchial Wall Thickening, a finding we are attempting to validate, was observed in all types of OI. Interested males with OI will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with OI. Smokers will not be excluded.

Arms, Groups and Cohorts

  • Adults with OI
    • 18 participants will be enrolled through in this pilot study. Interested males with OI will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with OI. This study is cross-sectional. At the participant’s one study visit, data will be obtained at a single point in time and reflect the patients’ current condition. All efforts will be made to complete all data collection and testing on the same day. However, procedures completed within ±12 months will be accepted. Evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. Participants will be enrolled regardless of OI type since BWT, a finding we are attempting to validate, was observed in all types of OI. Smokers will not be excluded.

Clinical Trial Outcome Measures

Primary Measures

  • proportion of restrictive lung physiology
    • Time Frame: 12 months
    • FEV1/FVC greater than or equal to 80%, which is obtained from PFT

Secondary Measures

  • Presence and severity of Bronchial Wall Thickening
    • Time Frame: 12 months
    • measurement of percent of bronchial diameter subsumed by wall thickness
  • Vital lung capacity
    • Time Frame: 12 months
    • Vital capacity/total lung capacity/chest volume prediction based on 1) readings by trained chest CT readers and 2) 3-D lung imaging calculation
  • Presences of pulmonary fibrosis
    • Time Frame: 12 months
    • Presence of pulmonary fibrosis based on readings by trained chest CT readers
  • Change in lung tissue
    • Time Frame: 12 months
    • location of bronchiectasis, and presence of atelectasis based on readings by trained chest CT readers

Participating in This Clinical Trial

Inclusion Criteria

  • Individuals who are able to give informed consent or have a legally authorized representative capable of giving consent on the subject's behalf – Individuals ages 18 and older of all races and sexes – Individuals who have been diagnosed with OI clinically and/or genetically Exclusion Criteria:

  • Individuals diagnosed with respiratory illness within 6 weeks of enrollment or undergoing diagnostic studies for an active illness. – Individuals with other skeletal dysplasia or genetic diagnosis – Individuals diagnosed with cardiopulmonary comorbidities that affect lung compliance

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Baylor College of Medicine
  • Provider of Information About this Clinical Study
    • Principal Investigator: Brendan Lee, Consortium PI – Baylor College of Medicine
  • Overall Official(s)
    • Vernon Sutton, MD, Principal Investigator, Baylor College of Medicine
    • Kathleen Raggio, Study Chair, Hospital for Special Surgery, New York
  • Overall Contact(s)
    • Dianne Nguyen, 713.798.6694, diannen@bcm.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.